Promising Remission with Reduced Bevacizumab and Pembrolizumab Dosage in a Patient with AT-rich Interaction Domain 1A Mutated Ovarian Clear-cell Carcinoma Refractory to Chemotherap... by Cheng-Wei Huang, Ruo-Han Tseng

Subjects: Get full text

A Case of Primary Lung Adenocarcinoma With Recurrent Brain Metastasis due to Transformation to Small Cell Carcinoma During Adjuvant Atezolizumab Therapy by Nao Kobayashi, Noriaki Sunaga, Masakiyo Yatomi, Ikuo Wakamatsu, Sohei Muto, Hayato Ikota, Rei Yamaguchi, Yoichi Ohtaki, Toshiteru Nagashima, Nobuteru Kubo, Tomomi Masuda, Yosuke Miura, Hiroaki Tsurumaki, Reiko Sakurai, Yasuhiko Koga, Takeshi Hisada, Toshitaka Maeno

Subjects: Get full text

Dissociated response and treatment outcome with immune checkpoint blockade in advanced cancer by Yaping Guan, Yu Cui, Yanhong Gong, Xiuju Liang, Xinyue Han, Yingcui Chen, Hong Xie, Yuekai Zhang, Baocheng Wang, Xin Ye, Jun Wang

Subjects: Get full text

Case report: A case of type 1 diabetes with diabetic ketoacidosis induced by envafolimab treatment in hepatocellular carcinoma by Youjia Li, Kai Qu, Xiuli Li, Xin Yang, Kanghuai Zhang, Jiao Xie

Subjects: Get full text

Fusobacterium nucleatum upregulates the immune inhibitory receptor PD-L1 in colorectal cancer cells via the activation of ALPK1 by Coco Duizer, Moniek Salomons, Merel van Gogh, Sanne Gräve, Freke A. Schaafsma, Maaike J. Stok, Merel Sijbranda, Raghuvandhanan Kumarasamy Sivasamy, Rob J. L. Willems, Marcel R. de Zoete

Subjects: Get full text

Efficacy of first-line chemotherapy combined with immunotherapy or anti-angiogenic therapy in advanced KRAS-mutant non-small cell lung cancer by Huiping Qiang, Yue Wang, Yao Zhang, Jingwen Li, Lincheng Zhang, Huawei Du, Xuxinyi Ling, Shuhui Cao, Yan Zhou, Runbo Zhong, Hua Zhong

Subjects: Get full text

Efficacy analysis of drug-eluting beads transcatheter arterial chemoembolization combining systemic chemotherapy and immune checkpoint inhibitors in unresectable intrahepatic chola... by Liu Song, Wang Qingdong, Yin Shunhang, Li Long, Zhao Guangsheng, Yu Guangji, Wang Dong

Subjects: Get full text

Prognostic value of systemic immune-inflammation index in patients with small-cell lung cancer treated with immune checkpoint inhibitors by Yusuke Hamakawa, Ayumi Hirahara, Akiko Hayashi, Kota Ito, Hiroyuki Shinohara, Aya Shiba, Yuko Higashi, Masaharu Aga, Kazuhito Miyazaki, Yuri Taniguchi, Yuki Misumi, Yoko Agemi, Yukiko Nakamura, Tsuneo Shimokawa, Hiroaki Okamoto

Subjects: Get full text

Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer by Satoshi Endo, Hisao Imai, Atsuto Mouri, Kasumi Tsukamoto, Kenji Masaki, Kosuke Hashimoto, Yu Miura, Ayako Shiono, Ou Yamaguchi, Junichi Nakagawa, Kyoichi Kaira, Kunihiko Kobayashi, Hiroshi Kagamu

Subjects: Get full text

Biomarkers in metastatic castration-resistant prostate cancer for efficiency of immune checkpoint inhibitors by Zixi Wu, Junbiao Zhang, Le Li, Zhihua Wang, Chunguang Yang

Subjects: Get full text

Late-onset and relapsed cytokine release syndrome after nivolumab treatment in a patient with head and neck squamous cell carcinoma: a case report by Tomoyuki Otsuka, Yoshiki Kojitani, Fumio Imamura, Junko Fukutake, Minako Nishio, Takashi Fujii, Toshihiro Kudo

Subjects: “…immune checkpoint inhibitor…”
Get full text

Effectiveness and safety of pembrolizumab, nivolumab, and atezolizumab as adjuvant therapy for high-risk muscle-invasive urothelial carcinoma: an indirect comparison by Wei Chen, Wei Chen, Soichiro Yoshida, Noriyoshi Miura, Shohei Fukuda, Hiroshi Fukushima, Yuma Waseda, Hajime Tanaka, Yasuhisa Fujii

Subjects: Get full text

Increased serum soluble PD-l1 levels in patients with advanced stages of chronic kidney disease by Ayaka Hayashi, Ayaka Hayashi, Hiroto Ishihara, Mayuko Kawabe, Kazuhiko Kato, Kazuhiko Kato, Akio Nakashima, Akio Nakashima, Izumi Yamamoto, Teppei Sakano, Teppei Sakano, Hiroe Kobashi, Makoto Morita, Makoto Morita, Takashi Yokoo, Mitsuyoshi Urashima

Subjects: Get full text

Comparisons of adverse events associated with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: a real-world disproportionality analysis based on the FDA... by Ruichen Gao, Wenjun Liang, Jintao Chen, Mingxia Yang, Xiaowei Yu, Xiaohua Wang

Subjects: Get full text

Machine-Learning Parsimonious Prediction Model for Diagnostic Screening of Severe Hematological Adverse Events in Cancer Patients Treated with PD-1/PD-L1 Inhibitors: Retrospective... by Seok Jun Park, Seungwon Yang, Suhyun Lee, Sung Hwan Joo, Taemin Park, Dong Hyun Kim, Hyeonji Kim, Soyun Park, Jung-Tae Kim, Won Gun Kwack, Sung Wook Kang, Yun-Kyoung Song, Jae Myung Cha, Sang Youl Rhee, Eun Kyoung Chung

Subjects: “…immune checkpoint inhibitor…”
Get full text

Suppression of MCP-1, IFN-γ and IL-6 production of HNSCC ex vivo by pembrolizumab added to docetaxel and cisplatin (TP) exceeding those of TP alone is linked to improved survival by Jana Wellhausen, Louisa Röhl, Michael Berszin, Irene Krücken, Irene Krücken, Veit Zebralla, Veit Zebralla, Markus Pirlich, Markus Pirlich, Matthaeus Stoehr, Matthaeus Stoehr, Susanne Wiegand, Susanne Wiegand, Susanne Wiegand, Andreas Dietz, Andreas Dietz, Theresa Wald, Theresa Wald, Gunnar Wichmann, Gunnar Wichmann

Subjects: “…PD-1:PD-L1 immune-checkpoint inhibitor (ICI) pembrolizumab…”
Get full text